AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04713826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BAY2586116, nasal spray administration.
Study NCT04894396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support
Description: An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. For medium to high arches with forefoot pain, featuring a cupped heel to cushion and stabilize the back of foot and a metatarsal pad to redistribute weight to relieve ball-of-foot discomfort. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
Study NCT04894396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aetrex L2300 Premium Memory Foam Orthotics
Description: An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
Study NCT05524181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Integrated Primary Care (TIPC)
Description: The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in the study.
Study NCT06127459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Guidance
Description: Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma).
Study NCT06127459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game
Description: Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
Study NCT06301191 — intervention group
Intervention type: DRUG
Intervention: Semaglutide, 1.0 mg/mL
Description: Semaglutide, 1.0 mg/mL
Study NCT06301191 — intervention group
Intervention type: DRUG
Intervention: Dipeptidyl Peptidase 4 inhibitor
Description: Dipeptidyl Peptidase 4 inhibitor
Study NCT06582186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualization of first voriconazole maintenance doses
Description: Individualization of first voriconazole maintenance doses
Study NCT04449211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Reconstructing the long bone defect with 3D-printed customised Titanium alloy implant
Study NCT05320887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Nicotine Content Vape with all flavor e-liquids
Description: Participants are randomly assigned to the order of each marketplace Group
Study NCT05320887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal nicotine content vape with tobacco e-liquids
Description: Participants are randomly assigned to the order of each marketplace Group
Study NCT05320887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low nicotine content vape with all flavor e-liquids
Description: Participants are randomly assigned to the order of each marketplace Group
Study NCT05320887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low nicotine content vape with tobacco e-liquids
Description: Participants are randomly assigned to the order of each marketplace Group
Study NCT05235516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: q3w iv
Study NCT05235516 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: EBRT
Description: 45-50.4Gy
Study NCT05235516 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBRT
Description: 45-50.4Gy
Study NCT05235516 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: BT
Description: ≥80Gy
Study NCT05235516 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BT
Description: ≥80Gy
Study NCT05235516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: qw iv
Study NCT05235516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: qw iv
Study NCT05235516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: q3w iv
Study NCT04971187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study NCT04971187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT04971187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04971187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT06013826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing
Description: Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
Study NCT06548997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: 5 μg/kg-maximum tolerated dose (MTD), single dose or two doses
Study NCT06548997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered the same volume as GZR18
Study NCT04901286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: Cycling in a lab environment
Study NCT04901286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Non-Immersive Virtual Reality
Description: Cycling with an environment simulated by non-immersive virtual reality
Study NCT04901286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Immersive Virtual Reality
Description: Cycling with an environment simulated by immersive virtual reality
Study NCT06086548 — intervention group
Intervention type: OTHER
Intervention: metabolomic on plasma sample
Description: metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
Study NCT04917185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture
Description: Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
Study NCT05473442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQU-001
Description: 20 mg pills of EQU-001
Study NCT05473442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 20 mg matching placebo pills
Study NCT05472532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient sampling.
Description: One or several bio-specimens will be sampled depending on the cohort :~* Blood (40 ml)~* Pleural Fluid (40 ml)~* Peritoneal liquid (40 ml)~* Solid tumors
Study NCT05473442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: 20 mg matching placebo pills
Study NCT03531242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Description: administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63
Study NCT05440240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous needle fasciotomy
Description: Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
Study NCT05440240 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous needle fasciotomy
Description: Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
Study NCT05440240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Depo-Medrol
Study NCT05440240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Isotonic saline
Study NCT04788810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of d12-Cl2BPA
Description: Administration of d12-Cl2BPA
Study NCT03824444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PODS
Description: Percutaneous Osseointegrated device for transhumeral patients
Study NCT05403775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printing guide plate
Description: 3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
Study NCT05403775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional guidance
Description: The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
Study NCT05807646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vein ligation first
Description: During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
Study NCT05807646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artery ligation first
Description: During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
Study NCT05946512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: yoga breathing techniques for dysfunctional breathing
Study NCT05946512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social contact
Description: social contact as active comparator
Study NCT05950620 — intervention group
Intervention type: OTHER
Intervention: Medical obesity management.
Description: Dietician visits, education, anti-obesity medications, and/or referral for metabolic-bariatric surgery as indicated by American Academy of Pediatrics guidelines for obesity management.
Study NCT05135962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic - rapid maxillary expansion
Description: Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
Study NCT05135962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic - slow maxillary expansion with leaf expander
Description: Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
Study NCT05135962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic - slow maxillary expansion with self leaf expander
Description: Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
Study NCT06334614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iReach
Description: The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
Study NCT05701566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality headset
Description: use of virtual reality headset during colonoscopy as a substitute to sedation.
Study NCT05701566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy with standard sedation.
Description: use of standard sedation during colonoscopy.
Study NCT05487742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
Study NCT05487742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo salin infusion
Description: salin infused as aplacebo for 72 hours
Study NCT06352255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital block
Description: Frost's H technique
Study NCT06352255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital block
Description: Frost's H technique
Study NCT05578287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-HER2 ADC
Description: Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
Study NCT05954767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IS-001
Description: IV injection of IS-001 drug substance with near infrared (NIR) imaging
Study NCT06219395 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
Study NCT06472713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome injection
Description: Mitoxantrone hydrochloride liposome injection once every 3 weeks for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
Study NCT06472713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: PD-1 blockade (comprising tislelizumab \<200 mg/cycle>, carrellimab \<200 mg/cycle>, or toripalimab \<240 mg/cycle>) once every 3 weeks for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
Study NCT04731532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical respiratory physiotherapy with thoracic vibration
Description: Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
Study NCT05738720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)
Description: Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.
Study NCT05738720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Programme
Description: Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test.
Study NCT05738720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test.
Study NCT04941079 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00269815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate HCl
Study NCT04814225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product 1
Description: Pea Protein powder
Study NCT04814225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product 2
Description: Pea \& Oat Protein Powder
Study NCT04814225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product 3
Description: Oat Protein Powder
Study NCT04814225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Whey Protein Isolate
Study NCT05023226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RM
Description: RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
Study NCT05023226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPVS
Description: LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
Study NCT05023226 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LPVS
Description: LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
Study NCT05099562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients received standardized acupuncture treatment. A blood sample of genomic DNA storage was taken from the back of the hand between the first and second metacarpals. Genotypes were obtained by oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis of peripheral neuropathy-associated SNPs.
Study NCT06432816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NANO-PSO
Description: NANO-PSO or Oil of pomegranate seed with nanotechnology, they are capsules with a net content of 640 mg with a dosage indicated by sponsor of 2 capsules in fast
Study NCT06432816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo physically identical to NANO-PSO capsules:~Soft gelatin capsules 640 mg edible oil 35for PLACEBO Oil edible, oval shape, 640 mg.